Navigation Links
Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
Date:6/19/2013

emissions lasting in excess of two years in the great majority of patients treated."  

Study participants were enrolled selected to receive either ibrutinib 420 mg (n=51) or 840 mg (n=34) as a once-daily, oral monotherapy. Both doses were associated with overall response rates of 71 percent. Del17p patients had an overall response rate of 68 percent. Two patients in the 420 mg dose arm had complete responses and 34 patients had partial responses. Across all relapsed or refractory patients, including the high risk patients, the estimated progression-free survival at 26 months was 75 percent. An additional 20 percent of patients treated with the 420 mg dose and 15 percent of patients taking the 840 mg dose achieved a partial response accompanied by lymphocytosis, an elevated blood lymphocyte count.

The majority of adverse events (AEs) observed in the study were considered to be Grade 1 or 2 in severity, including diarrhea, infections and fatigue. A total of six patients taking ibrutinib experienced an AE leading them to discontinue treatment with the drug. Severe AEs observed during the treatment period include pneumonia and dehydration (12 percent and six percent, respectively), as well anemia, neutropenia and thrombocytopenia (six percent, 15 percent and six percent, respectively). Grade 3-4 hematological toxicities were not common.

Data from this study were presented at the annual meeting of the American Society of Hematology in December 2012.

Study Design
The Phase 1b/2, open-label, multicenter study was designed to determine the safety, efficacy, pharmacokinetics and pharmacodynamics of ibrutinib in patients with relapsed or refractory CLL. The primary objective of the study was to determine the safety of the two fixed-dose regimens of ibrutinib, assessed by evaluating the frequency and severity of AEs. Secondary efficacy endpoints included: overall response rate, progression-free survival and an exploratory endpoint of overa
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
8. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
9. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
10. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
11. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... -- DeepResearchReports.com adds "2014 Deep Research Report on ... Deep Research Report on Global and China Tricalcium ... Photo - http://photos.prnewswire.com/prnh/20140731/132164 ... Global and China Potassium Nitrate  Industry" is a ... China and Global Potassium Nitrate  market. ...
(Date:7/31/2014)... -- IRIDEX Corporation (Nasdaq: IRIX ) today reported ... June 28, 2014.  , Revenues were $10.6 million ... million in the 2013 second quarter and up sequentially from ... the first six months of 2014 were $20.9 million, up ... last year. , Gross margin for the quarter was ...
(Date:7/31/2014)...  Cepheid (NASDAQ: CPHD ) today announced that ... invited investors to participate via webcast. ... NY Wednesday, August 13, 2014 at 9.10 a.m. ... New York, NY Thursday, September 4, 2014 ... Webcasts To access the live webcasts for these events, please ...
Breaking Medicine Technology:Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Cepheid to Webcast Upcoming Financial Presentations 2
... 2011 Surgical Information Systems ("SIS") announced today ... management systems as a key component of the ... Healthcare Information and Management Systems Society, February 20-24 ... presentations and solution demonstrations, SIS will showcase the ...
... Va., Feb. 17, 2011 Radiologic Associates of ... Campaign to increase awareness of opportunities to lower radiation ... of the Alliance for Radiation Safety in Pediatric Imaging.  ... additional training in ways to reduce radiation exposure, especially ...
Cached Medicine Technology:Surgical Information Systems Focuses on Surgery and Anesthesia as a Key Component of the EHR at HIMSS11 2Surgical Information Systems Focuses on Surgery and Anesthesia as a Key Component of the EHR at HIMSS11 3Radiologic Associates of Fredericksburg Announces Image Gently Campaign to 'Child Size' Doses for Children 2
(Date:8/1/2014)... (HealthDay News) -- Patients with the progressive, deadly respiratory ... a new weapon to battle the disease, the U.S. ... agency approved a new treatment, an inhaled spray called ... of Americans. COPD, which is often linked to smoking, ... emphysema. Patients with COPD may experience a ...
(Date:8/1/2014)... 01, 2014 According to new ... Geography (Asia-Pacific, North America, Europe, & ROW), by ... Fuel Type (Gasoline & Diesel), by After-Treatment Device ... Trends & Forecasts to 2019", defines and segments ... analysis of major countries in all the regions, ...
(Date:8/1/2014)... Over the past five years, ... technologies that have enabled cosmetic dentists to provide ... Moreover, the burgeoning elderly population has stimulated demand ... Due to long-term use of medications, which may ... dental fillings, veneers and implants. As more elderly ...
(Date:8/1/2014)... GlobalDatas new report, "United ... provides key market data on the United ... value, in millions of US dollars, volume ... dollars) within market segments - Electrosurgical RF ... Plasma Coagulation Generators. , To view the ...
(Date:8/1/2014)... Kathleen Doheny HealthDay Reporter ... control pills containing high doses of estrogen, along with ... cancer in women under 50, new preliminary research ... lead researcher Elisabeth Beaber, a staff scientist at the ... these formulations increase breast cancer risk while other formulations ...
Breaking Medicine News(10 mins):Health News:FDA Approves New Treatment for People With COPD 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 2Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 3Health News:Some Birth Control Pills May Up Breast Cancer Risk 2Health News:Some Birth Control Pills May Up Breast Cancer Risk 3
... Management Fundamentals for Healthcare module is now available online ... Georgia Center for Continuing Education,s Healthcare Management Certificate ... experience hands-on application to a work-related project, and learn ... efficient techniques for managing projects in a healthcare environment. ...
... State to Win Honor PITTSBURGH, May 14 MSA ... employee Wellness Program has received the "Gold Well Workplace ... is the first company headquartered in Pittsburgh, and just ... this fashion by demonstrating outstanding quality and excellence in ...
... voriconazole to its YeastOne(R) susceptibility plate for ... FDA-cleared antifungal agents- New Research-Use-Only Sensititre(R) Xtra ... including colistin and polymixin BCLEVELAND, May 14 ... company and premier provider of diagnostic systems ...
... time leg, foot or hand cramps can now get instant relief. ... has made it available for the first time via the Internet. ... pregnant women suffering from night time leg cramps, the problem is ... to be kept awake for hours during the night. This old ...
... Remind People to Eliminate Standing Water to Reduce Risk ... reported the first finding of West Nile Virus in ... and reminded residents of steps they can take to ... mosquito. The Department of Environmental Protection,s West Nile Virus ...
... play a role in heart muscle rejuvenation by attracting cells ... have been successfully used to halt or reverse cardiac injury ... occurs. , A new study that delivered embryonic stem ... found that the resulting mice demonstrated a capacity to recover ...
Cached Medicine News:Health News:New Online Project Management Fundamentals for Healthcare Module Available 2Health News:Wellness Program at MSA Receives National Recognition 2Health News:Wellness Program at MSA Receives National Recognition 3Health News:TREK to Introduce New In Vitro Diagnostic and Research-Use-Only Susceptibility Products at American Society for Microbiology General Meeting, Booth 1301 2Health News:TREK to Introduce New In Vitro Diagnostic and Research-Use-Only Susceptibility Products at American Society for Microbiology General Meeting, Booth 1301 3Health News:TREK to Introduce New In Vitro Diagnostic and Research-Use-Only Susceptibility Products at American Society for Microbiology General Meeting, Booth 1301 4Health News:Amish Formula From Caleb Treeze Organic Eliminates Night Time Cramps 2Health News:PA's First West Nile Positive Sample of 2009 Discovered in York County 2Health News:PA's First West Nile Positive Sample of 2009 Discovered in York County 3Health News:Stem cell transplant in mouse embryo yields heart protection in adulthood 2
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
... are liquid controls designed to ... procedures that detect Chlamydia trachomatis ... are specimen specific, they can ... or endocervical/urethral swabs throughout the ...
Liquichek Pediatric Control is a product designed to monitor important analytes for neonatal testing. This control monitors four bilirubin parameters at two clinically significant levels....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Medicine Products: